Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 15;33:376–390. doi: 10.1016/j.omtn.2023.07.010

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s)

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

PANoptosis signature predicts the prognosis and immunotherapy response of patients with PRAD

(A) The differences in survival probability between the high- and low-signature score groups. (B) Prognostic prediction of PANoptosis signature scores in the TCGA cohort. (C) Survival outcomes in melanoma patients treated with anti-PD-1 monotherapy (PMID30753825). (D and E) Correlation between the PANoptosis signature score and clinical response to cancer immunotherapy in patients with melanoma treated with anti-PD-1 monotherapy (PMID30753825). (F) Survival outcomes in melanoma patients treated with combined anti-PD-1 and anti-CTLA-4 therapy. (G and H) Correlation between the PANoptosis signature score and clinical response to cancer immunotherapy in patients treated with combined anti-PD-1 and anti-CTLA-4 therapy. CR, complete response; PR, partial response; PD, progressed disease; SD, stable disease. CR/PR, patient with CR or PR; SD/PD, patient with SD or PD.